Klin Farmakol Farm. 2004;18(2):90-95

Základní charakteristiky vybraných imunosupresiv

David Suchý1, Ilona Komzáková2, Milan Grundmann2
1 Oddělení klinické farmakologie, FN Plzeň
2 Ústav klinické farmakologie FNsP a ZSF Ostravské univerzity, Ostrava

Keywords: imunosuppression, transplantation, rejection, autoimmunity, immunosuppressive therapy.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Komzáková I, Grundmann M. Základní charakteristiky vybraných imunosupresiv. Klin Farmakol Farm. 2004;18(2):90-95.

Imunosupresivní terapie je stále se rozvíjející kapitolou imunofarmakologie s tendencí k stálému hledání optimální léčebné modality. Používá se heterogenní skupina látek s různým stupněm selektivity. Cílem článku je poskytnou základní charakteristiky některých používaných látek.

BASIC CHARACTERISTICS OF SELECTED IMMUNOSUPRESSANTS

Imunosupressive therapy is still developing part of immunopharmacology. Optimum therpeutic modalities are to be sought. Heterogenous group of drugs with different grade of selectivity is used. The goal of this article is provide a basic overview about some of these drugs.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boumpas DT, Chrousos GP, Wilder RL, Cuups TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med 1993; 119: 1198-1208. Go to original source... Go to PubMed...
    2. Barnes PJ, Adcock I. Anti-inflammatory actions of steroid: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-441. Go to original source... Go to PubMed...
    3. Klener P. Protinádorová chemoterapie. 1.vyd. Praha: Galen 1996.
    4. Bartůňková J. Současné možnosti léčebných zásahů do poruch imunity. Remedia 1998; 1: 31-37.
    5. Lukáš M. Současné možnosti medikamentózní léčby idiopatických střevních zánětů. Remedia 1994; 5: 302-313.
    6. Špinarová L, Toman J. Pharmacotherapy after heart transplantation. CorVasa 2000; 42: 335-340.
    7. Pavelka K. Současné postavení metotrexátu v léčbě revmatoidní artritidy. Čes revmatol 1995; 3: 16-23.
    8. Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348: 1357-1359. Go to original source... Go to PubMed...
    9. Quiroz Y, Herrera-Acosta J, Johnson RJ, Rodriguez-Iturbe B. Mycophenolatemofetil treatment in conditions different from organ transplantation. Transplant Proceed 2002; 34(7): 2523-2526. Go to original source... Go to PubMed...
    10. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11 (Suppl 8): p. S117. Go to PubMed...
    11. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24/6: 472-495. Go to original source... Go to PubMed...
    12. Martínek V, Matoušovič K, Špatenka J. Objev a využití cyklosporinu v klinické praxi. Praktický lékař 2002; 1: 14-20.
    13. Reidlichová M, Šenková A, Druga B, Kryštůfek P. Standardná farmakoterapia a liečba komplikácií u pacientov po transplantácii plúc. Klin Farmakol Farm 2003; 17: 177-182.
    14. Komzáková I, a kol. Terapeutické monitorování cyklosporinu A. Čes. slov. Farm. 2002; 51/4: 159-167.
    15. Špinarová L. Hypertenze po transplantaci srdce. Vnitř Lék. 1999; 45: 95 55-8. Go to PubMed...
    16. Ficková D, Vlček J, Topinková E. Role P-glykoproteinového transportu v klinicky významných lékových interakcích. Remedia 2002; 3: 207-213.
    17. Bordur WA, Noble NA. TGF-? in kidney fibrosis: a target for gene therapy. Kidney Int. 1997; 51: 1388-1396. Go to original source... Go to PubMed...
    18. Olyaei AJ, de Maltos AM, Bennet WM. Nephrotoxicity of immunosopressive druhgs: New insight and preventive strategie. Curr Opin Crit Care 2001; 7: 384. Go to original source... Go to PubMed...
    19. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA 2000; 238: 633. Go to original source... Go to PubMed...
    20. Maes BD, Vanrenterghem YFCH. Cyclosporine: advantages versus disadvantages vis-&-vis tacrolimus. Trans Proceed 2004; 36 (suppl.1): S40-49. Go to original source... Go to PubMed...
    21. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41 (11): 813-851. Go to original source... Go to PubMed...
    22. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004; 43 (2): 83-95. Go to original source... Go to PubMed...
    23. Třeška V. Transplantologie pro mediky. Praha: Karolinum 2002.
    24. Girman P, Saudek F. Sirolimusum (rapamycin) Remedia 2002; 5: 290-300.
    25. Sousa JE, Costa MA. Abizaid AC, et al. Sustained supression of neointimal proliferation by sirolimus-eluting stents. One year angiographic and ultrasound follow up. Circulation 2001; 104: 2007-2101. Go to original source... Go to PubMed...
    26. Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999; 19/10: 1127-1137. Go to original source... Go to PubMed...
    27. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735-740. Go to original source... Go to PubMed...
    28. Xia MQ, Hale G, Walkman H. Efficient complement mediated lysis of cells containing the CAMPATH-1(Cdw 52) antigen. Mol Immunol 1993; 30: 1089-1096. Go to original source... Go to PubMed...
    29. Ilex pharmaceuticals. Campath (alemtuzumab) package insert. San Antonio (TX): Ilex Pharmaceuticals, 2002; Jan.
    30. Lukáš M. Anticytokinová terapie Crohnovy nemoci a ulcerózní kolitidy. Remedia 2000; 5: 331-339.
    31. Maini R, et al. Infliximab (chimeric anti tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomittant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932-1939. Go to original source... Go to PubMed...
    32. Braun J, Brand J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised, controlled multicenter study. Lancet; 2002; 359: 1187-1193. Go to original source... Go to PubMed...
    33. Salfeld J, et al. Generation of fully human anti TNF antibody D2E7. Arthritis Rheum 1998; 41(suppl.9): S57.
    34. Fox DA. Cytokine blockade as a New Strategy to Treat Rheumatoid Arthritis. Inhibition of Tumor Necrosis Factor. Arch Intern Med. 2000; 160: 437-444. Go to original source... Go to PubMed...
    35. Gorman JO, Sachs KE, Davis JE, et al. Treatmant of AS by inhibiting TNF ?. Eng J Med. 2002; 346: 1349-1355. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.